ENHERTU® Plus Pertuzumab Granted Breakthrough Therapy HER2-Positive Breast Cancer: a promising new drug combo was explored by the Destiny-Breast09 trial. This study replaced IV
Yeon Hee Park, MD, PhD, Samsung Medical Center, Seoul, Korea, discusses findings from the Phase Ib/II Neo-PATH clinical trial Enhertu Plus Perjeta Boosts Survival in HER2-Positive Breast Cancer
Enhertu plus pertuzumab demonstrated highly statistically significant First-Line Enhertu Combo Gets Priority Review in HER2+ Metastatic
What is Enhertu? Enhertu is a new FDA approved treatment for breast cancer and other cancers. It's the first drug approved to treat Guy Jerusalem, MD, PhD, discusses the utility of fam-trastuzumab deruxtecan-nxki in HER2-positive breast cancer. Website:
ASCO25 Highlights: T-DXd & pertuzumab improves PFS in HER2+ metastatic breast cancer. #asco25 #bcsm Yelena Janjigian, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the ongoing DESTINY-Gastric03 study
Metastatic Breast Cancer Updates Exciting news in metastatic breast cancer! We have three press releases from 3 major studies (one for each BC subtype: triple
The FDA has granted breakthrough therapy designation to fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) in combination with pertuzumab for the first-line Enhertu plus pertuzumab granted Priority Review in the US as 1st DESTINY-Breast07: T-DXd+/- pertuzumab in patients with metastatic HER2+ breast cancer
SABCS 2022: DESTINY-Breast02 + DESTINY-Breast03 Gaia Griguolo, MD, University of Padova, Padova, Italy, discusses the characterization of genomic features associated with
Neo-PATH: TAHP for patients with HER2-positive breast cancer Dr. Gradishar on Managing Toxicities and Tailoring Treatment in HER2+ mBC
Dr. Tripathy on Trastuzumab Deruxtecan Versus T-DM1 in HER2-Expressing Breast Cancers Evolving Treatment Strategies for HER2-positive Breast Cancer
Finding appropriate doses for HER2 positive breast cancers HER2-Positive Breast Cancer: Promising New Drug Combo EVERYTHING you need to know About Herceptin Treatment
In this update from ASCO 2025, Dr. Maryam Lustberg, Chief of Breast Medical Oncology at Yale Cancer Center, breaks down the Dr. Sara Nunnery, director of breast cancer research at Tennessee Oncology, outlines key considerations when deciding whether Current and future HER2+, HR- metastatic breast cancer treatment approaches
Earn CME for related activities: Patients whose disease progresses or relapses on trastuzumab now Erika Hamilton, MD, Sarah Cannon Cancer Center, Nashville, TN, shares the primary results of the Phase III DESTINY-Breast02 Get ALL the info you need about HER2 +ve BREAST CANCER - HER2 +ve BREAST CANCER || Dr Liz O'Riordan In this video I'll
People who received Enhertu and Perjeta had a 44% lower risk of the cancer growing or dying from breast cancer than people who received THP Trastuzumab Deruxtecan in HER2-Low Breast Cancer: Who's the Right Patient? HER2CLIMB-05: tucatinib with trastuzumab and pertuzumab as maintenance therapy for HER2+ mBC
DESTINY-Breast09 Trial Shows Enhertu Plus Perjeta Significantly Reporting from the ESMO Congress 2021, Cristina Saura describes the outstanding results from the DESTINY-Breast03 study and
Dr. Hamilton on the Efficacy of Trastuzumab Deruxtecan in HER2-Low Breast Cancer 'Massive Improvement' With Second-Line Enhertu in HER2+ Breast Cancer - Medpage Today Dr Oleg Gluz speaks to ecancer at ESMO 2024 about results from the WSG-TP-II trial. This trial evaluated endocrine therapy plus
Maria Fernanda Mosele, MD, Gustave Roussy, Villejuif, France, talks on the significance of HER2 expression for the activity of In the trial, Enhertu in combination with pertuzumab reduced the risk of disease progression or death by 44% versus a taxane, trastuzumab and Dr. Kelly McCann, of the UCLA Health David Geffen School of Medicine, shares her expert insights on sequencing therapies for
Elena Garralda, MD, Vall d'Hebron Institute of Oncology, Barcelona, Spain, comments on the importance of the results of the Updated survival results of DESTINY-Breast03: T-DXd vs T-DM1 in HER2+ metastatic breast cancer
Sibylle Loibl, MD, PhD, German Breast Group, Neu-Isenburg, Germany, discusses the successes of trastuzumab deruxtecan for Ian Krop, MD, PhD, Smilow Cancer Hospital, Yale New Haven, CT, shares his key takeaways from the San Antonio Breast Cancer Alberto J. Montero, MD, Department of Hematology and Oncology at Cleveland Clinic, discusses the PERTAIN study in
ENHERTU Therapy: A Powerful New Cancer Treatment In the Phase III DESTINY-Breast09 trial, Enhertu (trastuzumab deruxtecan) and Perjeta (pertuzumab) significantly improved progression-free survival compared to
Endocrine therapy plus trastuzumab and pertuzumab shows excellent survival outcomes in HR and HE Wolfgang Janni, MD, PhD, University of Ulm, Ulm, Germany, discusses current treatments for HER2-positive, HR-positive Mette van Ramshorst, MD and Medical Researcher at the Netherlands Cancer Institute discusses the effect of trastuzumab-based
HER2CLIMB-05: tucatinib + trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic BC Trastuzumab deruxtecan shows benefit across HER2+ metastatic breast cancer subgroups #ESMO21 Expert Video Report on HER2-positive metastatic breast cancer
In this interview, William Gradishar, MD, Northwestern University Feinberg School of Medicine, discusses how treatment Trastuzumab Deruxtecan for Breast Cancer | NEJM
Oncoinfo – Istantanee di Oncologia: seguici su At SABCS 2019 Ian Krop (Breast Oncology Center, Dana-Farber Trastuzumab deruxtecan (Enhertu) is a type of HER2-targeted therapy called an antibody-drug conjugate that is made up of trastuzumab attached to Enhertu (trastuzumab deruxtecan) in combination with pertuzumab demonstrated a highly statistically significant and clinically meaningful improvement in
The phase 3 DESTINY-Breast09 clinical trial showed that first-line treatment with trastuzumab deruxtecan (T-DXd) plus Cristina Saura Manich, MD, PhD, Vall d'Hebron Institute of Oncology, Barcelona, Spain, presents results from the TULIP study,
Treatment for HER2+ metastatic breast cancer Trastuzumab deruxtecan in metastatic HER2+ breast cancer Erika Hamilton, MD, Sarah Cannon Cancer Center, Nashville, TN, provides an overview of the ongoing Phase III HER2CLIMB-05
Paolo Tarantino, MD, Dana-Farber Cancer Institute, Boston, MA, talks on clinical developments of HER2-low breast cancer, DESTINY-Breast02: T-DXd in HER2+ metastatic breast cancer previously treated with T-DM1
Trastuzumab Deruxtecan With or Without Pertuzumab Demonstrates Fam-trastuzumab deruxtecan-nxki (Enhertu), both as monotherapy and in combination with pertuzumab (Perjeta), displayed encouraging efficacy HER2-low expression in breast cancer
DESTINY-Gastric03: trastuzumab deruxtecan in HER2-overexpressing gastric cancer Treatment Sequencing Strategies in HER2-Positive Breast Cancer
Hope Rugo, MD, FASCO, University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, San Rupert Bartsch, MD, Medical University of Vienna, Vienna, Austria, talks on new agents in the field of HER2-positive metastatic Trastuzumab (Herceptin) & Pertuzumab (Perjeta) for HER2+ Breast Cancer: A COMPLETE Guide
Trastuzumab deruxtecan provides durable benefits to patients with heavily pretreated HER2-positive metastatic breast cancer, but Effect of Trastuzumab-based Therapy on Survival in Small, Node-Negative HER2-positive Breast Cancer
Erika Hamilton, MD, Sarah Cannon Research Institute, Nashville, TN, describes the rationale and study design of HER2CLIMB-05 TULIP: trastuzumab duocarmazine improved PFS in pre-treated HER2+ breast cancer
Results showed that Enhertu plus Perjeta reduced the risk of disease progression or death by 44% compared with THP. Median progression-free Enhertu plus Perjeta improved progression-free survival versus THP in patients with HER2-positive advanced or metastatic breast cancer Free CME/CE: HER2 is overexpressed in
Sequencing novel HER2-targeted therapies in metastatic breast cancer Dr Sara Hurvitz speaks to ecancer about the subgroup analyses from the randomised phase 3 study DESTINY-Breast03. Breakthrough Breast Cancer Drug Combo
Dr Bardia on Current Approaches to HER2+ Breast Cancer Management 32 month follow-up of MOUNTAINEER: tucatinib and trastuzumab in HER2+ mCRC
The significance of HER2 expression for the activity of trastuzumab deruxtecan DESTINY-Breast07: updated results of first line T-DXd in HER2+ breast cancer Alberto Montero Discusses PERTAIN Study in HER2-Positive Breast Cancer
FDA Fast-Tracks Breast Cancer Drug Combo The FDA granted Breakthrough status to Enhertu + Pertuzumab for HER2+ Treatment strategies for HER2+ metastatic breast cancer Trastuzumab deruxtecan plus pertuzumab may delay cancer growth for some HER2-positive advanced b
Dr. Jerusalem on Trastuzumab Deruxtecan in HER2+ Breast Cancer Trastuzumab deruxtecan shows benefit in patients with HER2 + mBC Expert Cancer Panel: Recurrent metastatic breast cancer w/ suspected pulmonary toxicity on therapy
Erika P. Hamilton, MD, discusses the efficacy of fam-trastuzumab deruxtecan-nxki in HER2-low breast cancer. Website: Clinical Impact of DESTINY-Breast09 in HER2+ Breast Cancer Management Study: Enhertu-Perjeta Combo Slows Growth of HER2 Metastatic
Erika Hamilton, MD, from the Sarah Cannon Research Institute in Nashville, TN, presents updated findings from the Phase III Dr Tolaney talks to ecancer at ASCO 2025 about data she presented from the phase 3 DESTINY-Breast09 clinical trial. This found
FDA Grants Breakthrough Therapy Designation to Frontline T-DXd DESTINY-Breast09: Will T-DXd + Pertuzumab Replace THP in First-Line HER2+ mBC? Dr Sara Hurvitz speaks to ecancer as part of SABCS 2022 about updated survival results of the randomised, phase 3
Highlights from ESMO: DESTINY-Breast03 Rupert Bartsch, MD, Medical University Vienna, Vienna, Austria, gives an overview of the current standard of care treatments for
Erika Hamilton, MD, Sarah Cannon Cancer Center, Nashville, TN, provides an overview of the preliminary data of the Phase Ib/II How do Trastuzumab (Herceptin) and Pertuzumab (Perjeta) work for HER2-positive breast cancer? In this video, Dr. Jennifer
PerELISA: overexpression of 13 genes associated with endocrine sensitivity in HR+/HER2+ BC Debu Tripathy, MD, discusses fam-trastuzumab deruxtecan-nxki versus ado-trastuzumab emtansine in HER2-expressing breast DESTINY-Breast01: a new "destiny" for HER2positive mBC patients?
Anti-HER2 Mechanisms of Approved HER2 Inhibitors Recorded on 2/20/2021 66-year-old female with recurrent, metastatic, ER-negative, PR-positive, HER2 positive breast cancer,
Aditya Bardia, MD, MPH, FASCO, discusses standard first-, second-, and third-line HER2-positive metastatic breast cancer The safety of ENHERTU was evaluated in 257 patients with unresectable or metastatic HER2-positive breast cancer who received at least 1 dose of Trastuzumab Deruxtecan With Pertuzumab May Delay Cancer
DESTINY-Breast03 results "will change my practice," says Amy Tiersten. John Strickler, MD, Duke University, Durham, NC, discusses final results from the Phase II MOUNTAINEER trial (NCT03043313), about therapy escalation/deescalation for patients with HER2 positive breast cancer. She summarises the discussions from the
Fabrice André, MD, PhD, Gustave Roussy, Villejuif, France, presents updated results from the DESTINY-Breast07 trial